Office of the United States Trade Representative August 27, 2021 – Federal Register Recent Federal Regulation Documents

In prior notices, the U.S. Trade Representative modified the action in the Section 301 investigation of China's acts, policies, and practices related to technology transfer, intellectual property, and innovation by excluding from additional duties certain medical-care products needed to address the COVID-19 pandemic. These exclusions are scheduled to expire on September 30, 2021. In light of developments in the production capacity of the United States in the subject products and continuing efforts in the battle against COVID-19, USTR is requesting public comments on whether to extend particular exclusions past September 30, 2021.